Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter E Clark

Showing results (11-20 of 239) with videos related to

Pageof 24
Sort By:
European Urology|February 10, 2009
Editorial comment on: Vaccine therapy in patients with renal cell carcinomaPeter E Clark
Oncology (Williston Park, N.Y.)|November 29, 2013
T1 high-grade bladder cancer recurring after BCG therapy: radical cystectomy is still the best approach. ProPeter E Clark
Expert Review of Anticancer Therapy|June 6, 2009
Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancerPeter E Clark
Kidney International|August 7, 2009
The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapyPeter E Clark
Urologic Oncology|August 18, 2015
Urothelial carcinoma with squamous differentiation: response to chemotherapy and radiationPeter E Clark
European Urology|January 4, 2011
Detection of tumor cells in the bone offers independent prognostic value in bladder cancer patients: the clinical and basic science perspectiveDavid J DeGraff, Peter E Clark
Current Opinion in Oncology|February 13, 2010
Bladder cancerTodd M Morgan, Peter E Clark
Cancer|September 19, 2008
The von Hippel-Lindau gene: turning discovery into therapyPeter E Clark, Michael S Cookson
Current Opinion in Oncology|March 23, 2006
Bladder cancerEric S Gwynn, Peter E Clark
Current Opinion in Oncology|April 9, 2008
Bladder cancerDaniel A Barocas, Peter E Clark
Pageof 24

Showing results (11-20 of 239) with videos related to

Sort By:
Pageof 24
European Urology|February 10, 2009
Editorial comment on: Vaccine therapy in patients with renal cell carcinomaPeter E Clark
Oncology (Williston Park, N.Y.)|November 29, 2013
T1 high-grade bladder cancer recurring after BCG therapy: radical cystectomy is still the best approach. ProPeter E Clark
Expert Review of Anticancer Therapy|June 6, 2009
Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancerPeter E Clark
Kidney International|August 7, 2009
The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapyPeter E Clark
Urologic Oncology|August 18, 2015
Urothelial carcinoma with squamous differentiation: response to chemotherapy and radiationPeter E Clark
European Urology|January 4, 2011
Detection of tumor cells in the bone offers independent prognostic value in bladder cancer patients: the clinical and basic science perspectiveDavid J DeGraff, Peter E Clark
Current Opinion in Oncology|February 13, 2010
Bladder cancerTodd M Morgan, Peter E Clark
Cancer|September 19, 2008
The von Hippel-Lindau gene: turning discovery into therapyPeter E Clark, Michael S Cookson
Current Opinion in Oncology|March 23, 2006
Bladder cancerEric S Gwynn, Peter E Clark
Current Opinion in Oncology|April 9, 2008
Bladder cancerDaniel A Barocas, Peter E Clark
Pageof 24